FDA Approves Emergent’s ACAM2000 Vaccine for Mpox Prevention, Pledges 50,000 Doses to Affected Regions

FDA Approval:
The FDA has approved Emergent BioSolutions' ACAM2000 vaccine for the prevention of mpox in individuals at high risk, marking the second vaccine authorized for mpox in the U.S.

Vaccine Details:
ACAM2000 is a single-dose vaccine that uses a live, infectious version of the vaccinia virus, administered through small punctures in the skin using a two-pronged needle.

Global Response:
Emergent has pledged to donate 50,000 doses of ACAM2000 to aid affected regions in Central Africa, supporting global health initiatives.

Expanded Indication:
The approval expands the use of ACAM2000, which was initially licensed for smallpox prevention in 2007, to include mpox prevention.

Global Health Context:
The approval comes as the global health community addresses a recent surge in mpox cases, with the WHO declaring the current outbreak a public health emergency of international concern.